Withdrawal of NINDS Participation in PAR-10-001, "Drug Discovery for Nervous System Disorders (R01)"

Notice Number: NOT-NS-12-008

Release Date: December 21, 2011

PAR-10-001; PAR-12-060

National Institute of Neurological Disorders and Stroke (NINDS)

This Notice informs potential applicants that, effective immediately, the National Institute of Neurological Disorders and Stroke (NINDS) will no longer accept applications under PAR-10-001, "Drug Discovery for Nervous System Disorders (R01)," beginning with the February 5, 2012 receipt date. Researchers seeking support for chemical optimization of small molecules probes for preclinical, in vivo proof-of-concept experiments for the purposes of drug discovery should consider PAR-12-060, "Solicitation of Validated Hits for the Discovery of in vivo Chemical Probes (R01)."

The following Institutes will continue to participate in PAR-10-001:

National Institute of Mental Health (NIMH)
National Institute on Aging (NIA)
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
National Institute on Drug Abuse (NIDA)

All other aspects of PAR-10-001 will remain unchanged.

Please direct all inquiries to:

Rebecca Farkas, PhD
Office of Translational Research
National Institute of Neurological Disorders and Stroke
6001 Executive Boulevard
Neuroscience Center/Room 2109
Bethesda, MD 20892
Telephone: (301) 496-1779
Fax: 301-402-1501
Email: [email protected]